Regeneron has partnered with Switzerland-based ModeX Therapeutics in a potential USD 1 billion plus collaboration combining the MSTAR multispecific antibody platform with Regeneron's proprietary binders to develop candidates targeting multiple biological pathways through single-molecule constructs. ModeX receives a USD 7 million upfront payment with eligibility for option exercise payments, development milestones and over USD 200 million per molecule in commercial milestones across multiple indications, including oncology and infectious diseases. The MSTAR technology utilises modular building blocks generating multispecific antibodies, with optimised efficacy and specificity for simultaneous intervention in disease pathways through natural protein structure integration.

ModeX president and CEO Gary Nabel highlighted the firm's potential expansion into immunology, oncology and metabolic diseases through the combination of its platform technology with Regeneron's industry leadership in antibody therapeutics development. The collaboration addresses complex diseases requiring multi-pathway intervention through single-administration, with potential improved therapeutic index over combination therapies. ModeX's pipeline includes candidates for solid tumours, haematologic malignancies and viral threats, leveraging multispecific targeting capabilities for enhanced potency and reduced resistance development.

According to PharmCube's NextBiopharm® database, this is the third licensing agreement that Regeneron enters this year. Click here to request a free trial for NextBiopharm®.